Chemokine Therapeutics Announces Addition to Senior Management Team
Chemokine Therapeutics Corp. announced the appointment of C. Richard Piazza as its new Chief Executive Officer (CEO). Mr. Piazza succeeds Dr. Hassan Salari who held the position since he founded the Company in 1998. Dr. Salari will continue to serve the Company as President and his role will be expanded to include the additional responsibilities as the Chief Scientific Officer. These changes will allow Dr. Salari to focus on Chemokine's accelerating product development while Mr. Piazza will use his financial and biotechnology industry experience to drive corporate initiatives.
Mr. Piazza has been a member of the board of directors for Chemokine Therapeutics since June 2001 and is presently the Chairman of the Board. Mr. Piazza has over 35 years of experience managing both public and VC-backed healthcare companies ranging from startup device and biotechnology companies to firms with combined annual revenues of over $600 million. He is currently Managing Director of Healthios, a healthcare merchant banking firm. He has served in numerous CEO positions including MAXIA Pharmaceuticals, VitaGen Inc., Marquest, Smith & Nephew SoloPak, Stimetics and Biolectron.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
